Group 1 - The article discusses the author's first treatment of Omeros in 2025, following extensive coverage in the previous year [1] - The author emphasizes the learning process involved in investing, viewing failures as tuition and successes as lessons learned, particularly in the healthcare sector [2] - The author has a beneficial long position in Omeros shares, indicating a personal investment interest [3] Group 2 - The author may engage in buying or selling shares of any mentioned company within the next 72 hours, suggesting potential volatility or changes in position [4] - Seeking Alpha clarifies that past performance does not guarantee future results and that no specific investment advice is being provided [5]

Omeros Corp (OMER) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jennifer Cook Williams - PrincipalGregory Demopulos - Founder, Chairman, CEO & PresidentDavid Borges - VP of Finance, Chief Accounting Officer & TreasurerSteve Brozak - President & Managing PartnerNadia Dac - CCO Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen only mode. After the company's remarks, we will conduct a question and answer s ...

Omeros Corp (OMER) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jennifer Cook Williams - PrincipalGregory Demopulos - Founder, Chairman, CEO & PresidentDavid Borges - VP of Finance, Chief Accounting Officer & TreasurerSteve Brozak - President & Managing PartnerNadia Dac - CCO Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen only mode. After the company's remarks, we will conduct a question and answer s ...

Omeros Corp (OMER) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Speaker0 Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen only mode. After the company's remarks, we will conduct a question and answer session. Please be advised that this call is being recorded at the company's request, and a replay will be available on the company's website for one week from today. I'll turn the call over to Jennifer Williams, Investor Relations for ...

Omeros Corporation OMER on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML).AML is the most fatal form of leukemia. It accounts for approximately 80% of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow.Omeros’ OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the can ...